HTGC

Business Context and Reporting Period

Company: Hercules Technology Growth Capital, Inc. (HTGC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: HTGC is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and taxed as a Regulated Investment Company (RIC). It provides debt and equity growth capital to technology-related and life-science companies at various stages of development.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total investment income increased to $15.6 million from $9.7 million, driven by higher average loan balances and yield from new originations.
• Expense Increase: Total operating expenses rose to $6.6 million from $4.5 million. This was primarily due to a 135% increase in interest and loan fees (linked to higher debt balances) and increased employee compensation due to headcount growth (29 to 45 employees).
• Realized Gains: Net realized gains surged to $3.0 million, compared to $0.3 million in the prior year, largely due to the sale of common stock in an advanced specialty materials company and acquisitions of a software and medical device company.
• Unrealized Depreciation: The company recorded a net unrealized depreciation of $0.9 million, reversing the $0.8 million appreciation in the prior year. This included a $5.3 million unrealized gain from a revision to marketability discounts on warrants, partially offset by other portfolio declines and a $0.4 million reduction for Citigroup's warrant participation.
• Liquidity: Cash and cash equivalents decreased to $13.8 million from $41.5 million, reflecting active investment deployment ($49.8 million in purchases) and dividend payments ($9.8 million).

Guidance, Outlook, and Risks

• Market Conditions: Management notes significant disruption in U.S. debt and equity capital markets due to subprime mortgage write-offs and credit risk re-pricing. This has reduced capital availability and may increase funding costs.
• Exit Strategy: The company anticipates achieving 8 to 10 exit events during 2008. As of March 31, 2008, three portfolio companies had achieved liquidity events.
• Subsequent Events:
  • Credit Facility: On May 7, 2008, the Credit Facility was amended and renewed with a reduced capacity of $135 million (down from $250 million) and a higher interest spread (LIBOR + 5.0%) to mitigate unused fees.
  • Acquisition: GlaxoSmithKline announced an agreement to acquire Sirtris Pharmaceuticals for approximately $720 million. HTGC anticipates a realized gain of approximately $2.2 million upon closing.
  • Dividend: A dividend of $0.34 per share was declared for the first quarter, payable June 16, 2008.
• Risks: Key risks include the potential for unrealized losses to become realized, portfolio company defaults due to economic downturns, and the inability to access capital markets or refinance debt on favorable terms.

Investor Verification Checklist

• Debt Capacity: Verify the impact of the reduced Credit Facility ($135M) on future investment deployment capabilities.
• Valuation Methodology: Review the Board's fair value determinations, particularly the $5.3 million unrealized gain from warrant discount revisions, given the lack of active markets for most assets.
• Concentration Risk: Assess the portfolio's exposure to the "Drug Discovery" and "Communications & Networking" sectors, which represent 17.0% and 21.9% of the portfolio, respectively.
• Non-Accrual Status: Confirm the status of the one loan on non-accrual status (fair value ~$2.6 million) and its potential impact on future income.
• Dividend Sustainability: Analyze the composition of the $0.34 dividend to determine the portion derived from ordinary income versus return of capital, noting the company's excess taxable income from 2007.